Apogee Therapeutics, Inc. Common Stock (APGE) - Total Assets
Based on the latest financial reports, Apogee Therapeutics, Inc. Common Stock (APGE) holds total assets worth $937.13 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See APGE net assets for net asset value and shareholders' equity analysis.
Apogee Therapeutics, Inc. Common Stock - Total Assets Trend (2022–2025)
This chart illustrates how Apogee Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
Apogee Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Apogee Therapeutics, Inc. Common Stock's total assets of $937.13 Million consist of 79.1% current assets and 20.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Apogee Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see APGE company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Apogee Therapeutics, Inc. Common Stock's current assets represent 79.1% of total assets in 2025, a decrease from 100.0% in 2022.
- Cash Position: Cash and equivalents constituted 14.0% of total assets in 2025, down from 99.9% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Apogee Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Apogee Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Apogee Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 26.57 | 18.55 | 15.24 |
| Quick Ratio | 26.57 | 18.55 | 15.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $713.45 Million | $501.15 Million | $142.07 Million |
Apogee Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Apogee Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.96 |
| Latest Market Cap to Assets Ratio | 5.27 |
| Asset Growth Rate (YoY) | 24.3% |
| Total Assets | $937.13 Million |
| Market Capitalization | $4.93 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Apogee Therapeutics, Inc. Common Stock's assets at a significant premium (5.27x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Apogee Therapeutics, Inc. Common Stock's assets grew by 24.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Apogee Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total assets of Apogee Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $937.13 Million | +24.30% |
| 2024-12-31 | $753.95 Million | +87.83% |
| 2023-12-31 | $401.40 Million | +163.99% |
| 2022-12-31 | $152.06 Million | -- |
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treat… Read more